CARLSBAD, Calif. and MADRID, Spain--(BUSINESS WIRE)--In response to industry feedback for deeper insights on the hot topic of biosimilars or follow-on biologics (FOBs), EBD Group today added a spotlight panel titled Biosimilars: Risk taking vs. Caution?
